Gene regulator profiling in live cells for drug development
Talus Bio is revolutionizing drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment.
Talus Bio is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators.
Talus spun out of two leading institutions in September 2020; the University of Washington and Altius Institute for Biomedical Sciences.
We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
Talus’ objective is to provide the first functional proteomics platform, named MARMOT, for drug discovery focused on studying full-length GRPs in their natural, unmodified cellular environment.
Use of the MARMOT platform will lead to a greater understanding of the role of GRPs in various diseases, and will facilitate the development of therapeutics against these disease-causing GRPs.